Down-regulation of SOSTDC1 promotes thyroid cancer cell proliferation via regulating cyclin A2 and cyclin E2.
Down-regulation of SOSTDC1 promotes thyroid cancer cell proliferation via regulating cyclin A2 and cyclin E2.
复制标题
SOSTDC1的下调通过调节细胞周期蛋白A2和细胞周期蛋白E2促进甲状腺癌细胞增殖
DOI：
10.18632/oncotarget.5566
复制
发表时间：
2015-10-13
期刊：
影响因子：
--
通讯作者：
Li Y
中科院分区：
文献类型：
--
作者：
Liang W;Guan H;He X;Ke W;Xu L;Liu L;Xiao H;Li Y
硬化素结构域包含蛋白1(SOSTDC1)在某些肿瘤中表达下调，并发挥肿瘤抑制作用。然而，SOSTDC1在甲状腺癌中的表达模式和生物学意义尚不清楚。我们证明了SOSTDC1在甲状腺癌中显著下调。异位过表达抑制甲状腺癌细胞增殖，诱导细胞周期停滞于G1/S期。此外，SOSTDC1过表达可抑制裸鼠移植瘤的生长。我们还发现，升高的SOSTDC1导致细胞周期蛋白A2和细胞周期蛋白E2的抑制。综上所述，我们的结果表明SOSTDC1在甲状腺癌中表达下调，可能成为治疗甲状腺癌的潜在靶点。
Sclerostin domain containing protein 1 (SOSTDC1) is down-regulated and acts as a tumor suppressor in some kinds of cancers. However, the expression pattern and biological significance of SOSTDC1 in thyroid cancer are largely unknown. We demonstrated that SOSTDC1 was significantly down-regulated in thyroid cancer. Ectopic over-expression of SOSTDC1 inhibited proliferation and induced G1/S arrest in thyroid cancer cells. Moreover, SOSTDC1 over-expression suppressed the growth of tumor xenografts in nude mice. We also found that elevated SOSTDC1 led to inhibition of cyclin A2 and cyclin E2. Together, our results demonstrate that SOSTDC1 is down-regulated in thyroid cancer and might be a potential therapeutic target in the treatment of thyroid cancer.